Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • HLA Today
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Research and News
    • Browse Research
      • Pre-transplant blinatumomab reduces MRD, time to HCT for pediatric patients with B-ALL
      • Novel cytogenetic-based risk scores predict HCT outcomes for patients with CLL
      • Cryopreservation of allogenic HCT grafts does not adversely impact early post-HCT outcomes
      • Precision medicine initiative uses whole genome sequencing to identify novel prognostic signatures and the impact of genomic subgroups in MDS allogeneic HCT patients
    • Browse News
    • About Our Research
    • Transplant Enews
      • Advances in Transplant Enews
      • Resource Connection Enews
  • Resources and Education
    • HCT Presentation Slides
      • Hemaglobinopathies, Transplant Consultation Timing Guidelines
      • Myeloproliferative Neoplasms (MPN), Transplant Consultation Timing Guidelines
    • Patient Resources
    • Financial Resources
    • Materials Catalog
    • Obstetrician Resources
    • Education Catalog
      • Sickle Cell Disease: Exploring treatment options and psychosocial care
      • Continuing Education Discontinuation
      • Building Yourself From The Ground Up
      • Advances in HCT Over Time
    • Technique Video
    • Umbilical Cord Blood Collection Training for Public Donation
  • Early Complications
  • Vaccinations
  • Long-Term Care Guidelines
  • Chronic GVHD
  • Post-Transplant Guidelines

Vaccinations


Research Spotlight
  • Haploidentical HCT is viable alternative to matched sibling HCT in patients with AML in CR1

    July 2019

  • Gait speed can predict survival, hospital use in older patients with blood cancers

    July 2019

  • Continued vigilance needed to prevent infections for HCT recipients

    January 2019

  • Post-Transplant Care
  • Vaccinations
  • Email
  • Print This Page

Related Resources

  • Post-HCT Care Education
  • Long-Term Care Guidelines
  • Chronic GVHD

Patient Resources

  • Post-Bone Marrow Transplant Care Guidelines
  • Allogeneic Transplant Process Booklet
  • Transplant Basics Videos

Vaccinations After Hematopoietic Cell Transplant

Routine administration of vaccinations is vital for prevention of infectious complications in hematopoietic cell transplant recipients.

Consensus Guidelines

Hematopoietic cell transplant recipients may remain immunocompromised far beyond 2 years post-transplant, especially individuals with chronic graft-versus-host disease (GVHD). Therefore, post-transplant patients should be routinely revaccinated after transplant until they regain immune competence.

The vaccination schedule below is based on international consensus guidelines for preventing infectious complications among all transplant recipients and is recommended for both autologous and allogeneic hematopoietic cell transplant (HCT) recipients. [1,2,3]

These recommended vaccinations are also included in our HCT Guidelines.

  • View Long-Term Care Guidelines (PDF)
  • Order a print version or access HCT Guidelines mobile app

Recommended Vaccinations/Schedulea


Pneumococcal Conjugate (PCV)

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 3-6 months
  • No. of doses: 3-4b

Tetanus, Diphtheria, Acellular Pertussisc

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 3-6 months
  • No. of doses: 3d

Haemophilus Influenzae Conjugate

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 3

Meningococcal Conjugate

  • Recommended for use after HCT: Follow country recommendations for general population
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 1

Inactivated Polio

  • Recommended for use after HCT: Yes
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 3

Recombinant Hepatitis B

  • Recommended for use after HCT: Follow country recommendations for general population
  • Time post-HCT to initiate vaccine: 6-12 months
  • No. of doses: 3

Inactivated Influenza

  • Recommended for use after HCT: Yearly
  • Time post-HCT to initiate vaccine: 4-6 months
  • No. of doses: 1-2e

Measles-Mumps-Rubella (livef,g)

  • Recommended for use after HCT: Measles: All children and seronegative adults
  • Time post-HCT to initiate vaccine: 24 months
  • No. of doses: 1-2h

Notes:

a) A uniform specific interval between doses cannot be recommended, as various intervals have been used in studies. As a general guideline, a minimum of 1 month between doses may be reasonable.

b) Following the primary series of three PCV doses, a dose of the 23-valent polysaccharide pneumococcal vaccine (PPSV23) to broaden the immune response might be given. For patients with chronic GVHD who are likely to respond poorly to PPSV23, a fourth dose of the PCV should be considered instead of PPSV23.

c) DTaP (diphtheria tetanus pertussis vaccine) is preferred, however, if only Tdap (tetanus toxoid-reduced diphtheria-toxoid reduced acellular pertussis vaccine) is available (for example, because DTaP is not licensed for adults), administer Tdap. Acellular pertussis vaccine is preferred, but the whole-cell pertussis vaccine should be used if it is the only pertussis vaccine available.

d) See references for consideration of an additional dose(s) of Tdap for older children and adults.

For children <9 years of age, two doses are recommended yearly between transplant and 9 years of age.

f) Measles, mumps and rubella vaccines are usually given together as a combination vaccine. In females with pregnancy potential, vaccination with rubella vaccine either as a single or a combination vaccine is indicated.

g) Not recommended <24 months post-HCT, in patients with active GVHD, and in patients on immune suppression.

h) In children, two doses are favored.

See reference [2] for vaccinations considered optional or not recommended for transplant recipients and for vaccinations for family, close contacts and health care workers.

References

  1. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation; Center for International Blood and Marrow Transplant Research (CIBMTR), American Society for Blood and Marrow Transplantation (ASBMT), European Group for Blood and Marrow Transplantation (EBMT), Asia-Pacific Blood and Marrow Transplantation Group (APBMT), Bone Marrow Transplant Society of Australia and New Zealand (BMTSANZ), East Mediterranean Blood and Marrow Transplantation Group (EMBMT) and Sociedade Brasileira de Transplante de Medula Ossea (SBTMO). Co-published in Biol Blood Marrow Transplant, 2012, 18(3): 348-371; Bone Marrow Transplant, 2012, 47(3): 337-341; and Hematol Oncol Stem Cell Ther, 2012, 5(1): 1-30. Access
  2. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biol Blood Marrow Transplant. 2009; 15(10): 1143-1238. Access
  3. Ljungman P, Cordonnier C, Einsele H, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009; 44(8): 521-526. Access
  • Email
  • Print This Page

Slides may be downloaded and used without permission for one-time presentation or personal use.  For publication, use in print or web, or repeated presentations, please submit a Copyright Request Form.

Transplant Indications and Outcomes

  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • HLA Today

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources and Education

  • HCT Presentation Slides
  • Patient Resources
  • Financial Resources
  • Materials Catalog
  • Obstetrician Resources
  • Education Catalog
  • Technique Video
  • Umbilical Cord Blood Collection Training for Public Donation

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2022 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright